H Ansari1,2, D E Beaton3,4,5, R Sujic1, N K Rotondi1, J D Cullen1, M Slater6, J E M Sale1,7, R Jain8, E R Bogoch9,10. 1. Musculoskeletal Health & Outcomes Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. 2. Psychiatry, The Hospital for Sick Children, Toronto, ON, Canada. 3. Musculoskeletal Health & Outcomes Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. dbeaton@iwh.on.ca. 4. Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada. dbeaton@iwh.on.ca. 5. Institute for Work & Health, University of Toronto, Toronto, ON, Canada. dbeaton@iwh.on.ca. 6. Department of Community & Family Medicine, St. Michael's Hospital, Toronto, ON, Canada. 7. Institute for Work & Health, University of Toronto, Toronto, ON, Canada. 8. Osteoporosis Canada, Toronto, ON, Canada. 9. Mobility Program, St. Michael's Hospital, Toronto, ON, Canada. 10. Department of Surgery, University of Toronto, Toronto, ON, Canada.
Abstract
We evaluated gender imbalance in osteoporosis management in a provincial coordinator-based fracture prevention program and found no difference by gender in treatment of high-risk fragility fracture patients. This establishes that a systemic approach with interventions for all fragility fracture patients can eliminate the gender inequity that is often observed. INRODUCTION: The purpose of this study was to evaluate an Ontario-based fracture prevention program for its ability to address the well-documented gender imbalance in osteoporosis (OP) management, by incorporating its integrated fracture risk assessments within a needs-based evaluation of equity. METHODS: Fragility fracture patients (≥ 50 years) who were treatment naïve at screening and completed follow-up within 6 months of screening were studied. Patients who underwent bone mineral density (BMD) testing done in the year prior to their current fracture were excluded. All participants had BMD testing conducted through the Ontario OP Strategy Fracture Screening and Prevention program, thus providing us with fracture risk assessment data. Our primary study outcome was treatment initiation at follow-up within 6 months of screening. Gender differences were compared using Fisher's exact test, at p < 0.05. RESULTS: After adjusting for subsequent fracture risk, study participants did not show a statistically significant gender difference in pharmacotherapy initiation at follow-up (p > 0.05). 68.4% of women and 66.2% of men at high risk were treated within 6 months of screening. CONCLUSION: Needs-based analyses show no difference by gender in treatment of high-risk fragility fracture patients. An intensive coordinator-based fracture prevention model adopted in Ontario, Canada was not associated with gender inequity in OP treatment of fragility fracture patients after fracture risk adjustment.
We evaluated gender imbalance in osteoporosis management in a provincial coordinator-based fracture prevention program and found no difference by gender in treatment of high-risk fragility fracturepatients. This establishes that a systemic approach with interventions for all fragility fracturepatients can eliminate the gender inequity that is often observed. INRODUCTION: The purpose of this study was to evaluate an Ontario-based fracture prevention program for its ability to address the well-documented gender imbalance in osteoporosis (OP) management, by incorporating its integrated fracture risk assessments within a needs-based evaluation of equity. METHODS:Fragility fracturepatients (≥ 50 years) who were treatment naïve at screening and completed follow-up within 6 months of screening were studied. Patients who underwent bone mineral density (BMD) testing done in the year prior to their current fracture were excluded. All participants had BMD testing conducted through the Ontario OP Strategy Fracture Screening and Prevention program, thus providing us with fracture risk assessment data. Our primary study outcome was treatment initiation at follow-up within 6 months of screening. Gender differences were compared using Fisher's exact test, at p < 0.05. RESULTS: After adjusting for subsequent fracture risk, study participants did not show a statistically significant gender difference in pharmacotherapy initiation at follow-up (p > 0.05). 68.4% of women and 66.2% of men at high risk were treated within 6 months of screening. CONCLUSION: Needs-based analyses show no difference by gender in treatment of high-risk fragility fracturepatients. An intensive coordinator-based fracture prevention model adopted in Ontario, Canada was not associated with gender inequity in OP treatment of fragility fracturepatients after fracture risk adjustment.
Authors: Alexandra Papaioannou; Suzanne Morin; Angela M Cheung; Stephanie Atkinson; Jacques P Brown; Sidney Feldman; David A Hanley; Anthony Hodsman; Sophie A Jamal; Stephanie M Kaiser; Brent Kvern; Kerry Siminoski; William D Leslie Journal: CMAJ Date: 2010-10-12 Impact factor: 8.262
Authors: Patrick Haentjens; Jay Magaziner; Cathleen S Colón-Emeric; Dirk Vanderschueren; Koen Milisen; Brigitte Velkeniers; Steven Boonen Journal: Ann Intern Med Date: 2010-03-16 Impact factor: 25.391
Authors: D E Beaton; M Vidmar; K B Pitzul; R Sujic; N K Rotondi; E R Bogoch; J E M Sale; R Jain; J Weldon Journal: Osteoporos Int Date: 2016-10-21 Impact factor: 4.507
Authors: W D Leslie; C Berger; L Langsetmo; L M Lix; J D Adachi; D A Hanley; G Ioannidis; R G Josse; C S Kovacs; T Towheed; S Kaiser; W P Olszynski; J C Prior; S Jamal; N Kreiger; D Goltzman Journal: Osteoporos Int Date: 2010-10-22 Impact factor: 4.507
Authors: W D Leslie; L M Giangregorio; M Yogendran; M Azimaee; S Morin; C Metge; P Caetano; L M Lix Journal: Osteoporos Int Date: 2011-04-08 Impact factor: 4.507
Authors: J E M Sale; A Yang; V Elliot-Gibson; R Jain; R Sujic; D Linton; J Weldon; L Frankel; E Bogoch Journal: Osteoporos Int Date: 2021-01-20 Impact factor: 4.507
Authors: Joanna E M Sale; Matthew Gray; Daniel Mancuso; Taucha Inrig; Gilles Boire; Marie-Claude Beaulieu; Larry Funnell; Earl Bogoch Journal: Rheumatol Int Date: 2018-10-26 Impact factor: 2.631